Five pharmacotherapies were selected for comparison in this placebo controlled trial: Nicotine Lozenge, Nicotine Patch, Bupropion, Nicotine Patch + Nicotine Lozenge, and Bupropion + Nicotine Lozenge.1 These therapies were selected for several reasons. The nicotine lozenge was selected because there was limited evidence regarding its efficacy. The 2008 PHS Guideline Update identified only one randomized placebo-controlled trial evaluating the lozenge, and thus gave the lozenge a “B” level strength-of-evidence rating. The single placebo-controlled trial on the lozenge suggests that it is both acceptable to smokers and highly efficacious.8
